|
|
||||||||
Immunology Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
Earlier studies describing the minimal requirements of ligand density on the APC surface (5, 6), and the more recent reports identifying minimal threshold levels of TCR triggering (7, 8) as a prerequisite for T cell activation collectively suggest that the APC activity of B cells can be modulated by its ability to bind Ag. Thus, concentration of free Ag, efficiency of Ag capture, and the efficiency with which the Ag is processed are likely to play important roles in defining the ability of Ag-activated B cells to present Ag (4). Our own results have revealed that the APC function of a B cell, with its consequent effects on Th recruitment capacity, is regulated by a complexity of parameters that include not only affinity of sIg receptor for epitope on Ag (9), but also the kinetics of this interaction (10) and competitive processes between sIg receptor and secreted Ig for Ag (11). Indeed, it is the collective outcome of these processes that eventually determines the hierarchy of immunodominance observed against B cell epitopes displayed on multideterminant Ags (9, 10, 11, 12, 13).
The discrimination of effector CD4 T cells into the Th1 and Th2 subsets (14, 15) offers an Ag-presenting B cell the option of selectivity in terms of Th recruitment. While, in principle, such B cells are known to be capable of interacting with both subsets (16, 17, 18), recent data suggest a preference for activating Th2 cells (19, 20, 21). However, the studies of Murray et al. (22) demonstrating a key role for ligand density on an APC for determining the relative extents of Th1 vs Th2 differentiation and activation add yet another level of intricacy to these issues. This is particularly true given our earlier findings that the efficiency of an Ag-activated B cell as APC, also a consequence of ligand density, is a variable that is under the influence of a variety of factors (9, 10, 11). Thus, it is likely that parameters that regulate Ag recognition by B cells can also influence the relative extent of Th cells recruited by it.
In this report, we have attempted to address these issues using two model synthetic peptide immunogens, peptides G28CT3 and G41CT3. Both peptides shared an identical amino acid sequence except for variations in two positions. We have earlier shown that these peptides prime a common pool of Th cells equally well and that they induce B cells of identical fine specificities, although peptide G28CT3 is more immunogenic (10). Enhanced immunogenicity of peptide G28CT3 could be ascribed to the higher on-rate of binding to specific B cells relative to peptide G41CT3, which in turn ensured a more efficient B cell-mediated recruitment of T cell help (10). Thus, peptides G41CT3 and G28CT3 appeared to represent useful models for examining the influence of Ag-binding parameters on selective engagement of Th subsets by activated B cells. We show here that on-rates of Ag binding to B cells can regulate the relative proportion of Th1 vs Th2 cells that are recruited by Ag-specific B cells, with a bias toward increased Th1 recruitment at higher on-rates. Further, subtle changes in Ag sequence, which do not induce any obvious structural changes, can nevertheless dramatically influence the kinetics of Ag recognition by B cells.
| Materials and Methods |
|---|
|
|
|---|
Heavy chain-specific horseradish peroxidase-labeled secondary Abs, goat anti-mouse IgG1, and goat anti-mouse IgG2a (both heavy chain specific) were purchased from Sigma Chemical (St. Louis, MO). Magnetic beads for panning of T and B cells were obtained from Dynal (Oslo, Norway). ELISA kits for measurement of cytokines were purchased from Genzyme (Cambridge, MA) and F-moc-amino acid derivatives for peptide synthesis from Novabiochem (Laufelfingen, Switzerland).
Peptide synthesis
Peptides were synthesized by the solid phase method (23, 24) on
a Millipore 9050 automated peptide synthesizer (Millipore, Bedford, MA)
using the F-moc chemistry (25). Crude peptides were purified to at
least 95% purity by reverse phase HPLC on a C-18 column (15 µ,
Pak, 19 x 300 mm; Waters, Milford, MA) using an
aqueous gradient of 0 to 70% acetonitrile in 0.1% trifluoroacetic
acid. Identities of all peptides were ascertained by amino acid
analysis.
Animals and immunizations
Female BALB/c mice (68 wk old) were obtained from the small animal breeding facility at the National Institute of Nutrition (Hyderabad, India). Immunizations were generally given i.p. with a dose of 50 µg/mouse as an emulsion in CFA (except where otherwise indicated). For polyclonal sera, mice were bled from the retro-orbital plexus at the indicated times.
Generation of anti-G41CT3 mAbs
Female BALB/c mice immunized with a single dose (50 µg/mouse) of peptide G41CT3 in CFA were then subsequently boosted i.v. with 50 µg each of soluble peptide in PBS. Three days later, the highest responder from the group was taken for the generation of IgG-secreting hybridomas. Polyethylene glycol-mediated fusion to hypoxanthine-aminopterin-thymidine-sensitive myeloma derivative SP2/O-Ag 14, maintenance of derived lines, and limiting dilution cloning were essentially as described earlier (26). The secretion of Ab in culture supernatants was screened by ELISA against peptide-coated wells, and only wells showing relatively higher Ab levels (ELISA readings of >1.0) were selected for subcloning and subsequent analysis. All of the five IgG mAbs thus obtained were found to be specific for the DPAF segment (residues 47) on peptide G41CT3, as determined by mapping against an overlapping G41-derived peptide panel using a protocol that has been previously described (10).
Enzyme-linked immunosorbent assays
Plates were coated with 2 µg of peptide/well in 100 µl of PBS (pH 7.2) at 37°C for 3.5 h. Subsequently, they were blocked with 300 µl/well of a 5% solution of fat-free dry milk powder in PBS at 37°C for 1 h. Then, 100 µl of the appropriate dilution of mouse antiserum was added and incubated at 37°C for 1 h. After washing, bound Ab was detected with horseradish peroxidase-labeled secondary Ab (37°C, 1 h) followed by color development with o-phenylenediamine as chromogen. Absorbance was measured at 490 nm.
For competitive ELISA experiments, antisera were used at dilutions representing 50% of titer value. Twofold higher concentrations of antiserum and competitor peptide were mixed in equal volumes and incubated for 10 min at room temperature. This was then added to duplicate wells at 100 µl/well. The remaining procedure was as described above.
Enrichment of B cell populations
For enrichment of T cells, lymph node cells (LNCs) from either immune or nonimmune mice were first depleted of RBCs by lysis with ammonium chloride, and subsequently adherent cells were removed by panning on plastic plates at 37°C for 1 h. Nonadherent cells were collected and diluted to a cell concentration of 5 x 107 cells/ml. B cells were depleted from this population by two rounds of panning with Dynabeads mouse anti-B220 (4 x 108 beads/ml; Dynal) following the recommended protocol of the manufacturer.
To obtain enriched B cells, mice immunized with peptide G41CT3 were boosted 3 wk later with a 50 µg/mouse dose of G41CT3 in PBS given i.v. Three days later, the spleen was removed and depleted of RBCs, following which adherent cells were removed by panning as described above. Nonadherent cells were diluted to 5 x 107 cells/ml, and T cells were depleted by two rounds of panning with Dynabeads anti-mouse Thy1.2 (4 x 108 beads/ml; Dynal) as recommended by the manufacturer. The resultant enriched B cells were then treated with mitomycin C at a final concentration of 50 µg/ml at 37°C for 20 min. Cells were washed thoroughly in culture medium before use. When unprimed B cells were required, an identical protocol was followed except that the splenocytes were taken from nonimmune mice. The purity of B cells obtained by such a protocol was found to be between 85 and 90% upon analysis by flow cytometry.
Lymphocyte cultures and cytokine estimations
BALB/c mice were immunized s.c. at the tail base with 50 µg/mouse of peptide G41CT3 as an emulsion in CFA. Seven days later, the mice were sacrificed and inguinal lymph nodes removed. LNCs, at 5 x 105 cells/well, were cultured in duplicate in 200 µl of RPMI 1640 containing 10% FCS, gentamicin (2 mg/L), and 2-ME (0.05 mM) in wells of a 96-well plate. In addition, the indicated peptide at a final concentration of 30 µM (previously identified as optimal; 10 was also included as challenge Ag. Cultures were incubated at 37°C in a humidified atmosphere of 5% carbon dioxide for 48 h, at which point supernatants were removed for quantitation of cytokines. Preliminary experiments identified this time point as optimal for the determination of all relevant cytokines. In experiments employing enriched B and T cells, cocultures were set up with 2 x 105 cells/well of each culture.
The cytokines IL-2, IL-4, and IFN-
were measured in a sandwich ELISA
protocol using commercially available kits (Duoset, Genzyme), as was
also IL-10 (Intertest-10x, Genzyme). The recommended protocol of the
manufacturer was followed in all cases, and quantitation was against a
standard curve obtained for individual cytokine standards provided by
the manufacturer, after subtracting background in culture wells where
no Ag was added.
Determination of on-rates
Equal volumes of the appropriate anti-G41CT3 mAb and the relevant peptide were mixed at room temperature, and time-dependent Ab binding in terms of quenching of tryptophan fluorescence was continuously monitored over a 100-min period in a Shimadzu RF-1501 spectrofluorometer. The excitation wavelength used was either 280 or 290 nm, depending on the Ab, and emission was measured at 330 nm. The final Ab concentration employed was 200 nm (except where indicated), whereas the peptide concentration employed was 20 µM (except where indicated). The extent of fluorescence quenching was used to determine unbound Ab concentrations as a function of time; values for kon (association rate constant) were calculated as described earlier (10). Values for kon reported are the mean (±SD) of three independent determinations.
| Results |
|---|
|
|
|---|
Both peptides G41CT3 and G28CT3 have been described earlier (10),
and their sequences are given in Figure 1
. They represent single amino
acid-substituted analogues of a model peptide, PS1CT3, for which the
sequence has also been included in Figure 1
for the sake of comparison.
The first 15 residues of peptide PS1CT3 (segment PS1) represent a known
B cell epitope derived from the pre-S1 sequence of the hepatitis B
surface Ag (27). The carboxyl-terminal 21-residue sequence (segment
CT3) corresponds to the promiscuous Th cell epitope identified from the
circumsporozoite protein of the malaria parasite, Plasmodium
falciparum (28). Separating the B and T cell epitopes is a
spacer of two glycine residues at positions 16 and 17 (Fig. 1
). Peptide
G41CT3 is an analogue of peptide PS1CT3 in which the proline residue at
position 14 was substituted by glycine, whereas the amino-terminal
histidine residue was substituted for glycine in peptide G28CT3 (Fig. 1
). We have already shown earlier that, akin to peptide PS1CT3, both
peptides G41CT3 and G28CT3 exist predominantly in a random structure in
solution as indicated by their circular dichroism (CD) spectra (10).
|
In earlier studies, we showed that, similar to peptide PS1CT3,
both peptides G41CT3 and G28CT3 induce a T-dependent primary B cell
response in BALB/c mice (10). In all three cases, the primary IgG
response was directed, at least predominantly, against a tetrapeptide
segment between positions four and seven (sequence DPAF, Fig. 1
),
indicating that the amino acid variations in peptides G41CT3 and G28CT3
do not affect the fine specificity of B cells induced in the primary
IgG response (10). Interestingly, however, peptide G28CT3 was markedly
more immunogenic than peptide G41CT3. This difference in immunogenicity
could be ascribed to the greater ability of peptide G28CT3 to induce a
Th cell recall response by peptide-primed B cells (10). For example,
either total LNCs or enriched splenic B cells from peptide
G41CT3-primed mice gave markedly elevated T cell proliferative
responses with peptide G28CT3 as the challenge Ag relative to that when
challenged with peptide G41CT3. Thus, it was of interest to
determine whether peptides G41CT3 and G28CT3 also showed differences in
relative activation of Ag-specific Th subsets.
Our initial experiments probed for the induction of cytokines
diagnostic of Th1- and Th2-type responses in ex vivo cultures of LNCs
from G41CT3-primed mice, when either peptide G41CT3 or peptide G28CT3
was added as the challenge Ag. As shown in Figure 2
A, recall of G41CT3-primed
LNCs with peptide G41CT3 yielded a cytokine spectrum that was heavily
dominated by IL-10, indicative of a predominantly Th2-type response. In
contrast, however, a challenge with peptide G28CT3 resulted in a five-
to six-fold enhancement in both IL-2 and IFN-
levels, whereas the
Th2-type cytokines IL-4 and IL-10 were relatively unaffected (Fig. 2
A). These results suggest that whereas peptide G41CT3
induces a dominant recruitment of Th2 effectors from G41CT3-primed
LNCs, recruitment in the presence of peptide G28CT3 is
comparably distributed between both Th1 and Th2 subsets from the same
pool.
|
Differential cytokine induction by peptides G41CT3 and G28CT3 is due to Ag presentation by activated B cells
The experiments described above suggested that the observed
differences in the cytokine patterns as a result of challenge with
either peptide G41CT3 or G28CT3 of G41CT3-primed LNCs could be due to B
cells functioning as APCs. We examined this possibility in a relatively
more defined experiment in which purified CT3-primed T cells were
cocultured with mitomycin C-treated enriched splenic B cells from mice
primed with peptide G41CT3. These cultures were then challenged with
optimal concentrations of either peptide G41CT3 or G28CT3, and the
resulting cytokines produced measured. As shown in Table I
, the results obtained here were
entirely consistent with those shown in Figure 2
A in that
significantly higher levels of both IL-2 and IFN-
were induced by
G41CT3-primed B cells when G28CT3 was added as challenge Ag as opposed
to when G41CT3 was employed. On the other hand, IL-4 and IL-10 levels
were comparable with both of the challenge peptides (Table I
). In
separate experiments, we observed that pretreatment of G41CT3-primed B
cells with chloroquine (300 µM, 20 min at 37°) before inclusion in
such cultures inhibited both IFN-
and IL-10 production to barely
detectable levels (<15 pg/ml). This was true regardless of whether
peptide G28CT3 or G41CT3 was used as the challenge Ag (data not shown),
implying that Ag processing and, consequently, its intracellular uptake
were necessary for the differences observed in Table I
. Essentially
similar results were also obtained when G41CT3-primed B cells were
first fixed with 0.1% paraformaldehyde before inclusion in the
coculture (data not shown), further supporting the view that Ag uptake
and processing are necessary. We also confirmed in these
experiments that the cytokines measured were a product of the
CD4+ T cells in selective depletion studies. Thus, while
depletion of CD8+ T cells from CT3-primed T cells had no
significant effect on the results shown in Table I
, selective
CD4+ depletion virtually abrogated the response, reducing
the levels of all indicated cytokines to those that were barely
detectable (data not shown).
|
|
/IL-10 ratios between 5 and 7 in three experiments).
This finding further supports the conclusion that the results in Table I
The observation that differential cytokine induction by the two
analogous peptides was dependent on the inclusion of Ag-primed, but not
unprimed, B cells in the coculture implicated the involvement of B cell
Ag receptor (BCR)-mediated uptake of Ag. To confirm this
conjecture, peptide G28CT3 challenge of B-T cocultures was
performed as described in Table I
, except that varying concentrations
of a peptide representing the B cell epitope segment of peptide G28CT3
(residues 115, segment G28) were also included. The latter peptide
was added as a competitive inhibitor of peptide G28CT3 binding to
specific BCR (10). Since peptide G28 lacked the T cell epitope,
inhibition of peptide G28CT3 recognition by B cells was also expected
to negatively influence T cell recall responses. As shown in Figure 3
A, peptide G28, but not its
scrambled analogue, induced a striking dose-dependent inhibition of
both IFN-
and IL-10 secretion to nearly basal levels at higher G28
concentrations. This clearly suggests that the induction of both
IFN-
and IL-10 seen in Table I
represents the outcome of
BCR-mediated uptake of peptide by Ag-specific B cells, followed by its
presentation to CT3-specific T cells. Also notable was the observed
effect of competitor peptide (G28) concentration on IFN-
/IL-10
ratios as depicted in Figure 3
B. The overwhelming dominance
of the Th1 cytokine was found to diminish as peptide G28 concentration
increased, implying a relationship between efficacy of Ag uptake and
the relative extent of Th1 vs Th2 stimulation.
|
Peptides G41CT3 and G28CT3 also induce qualitatively distinct anamnestic IgG responses from G41CT3-primed B cells
Differential engagement of the Th1 vs the Th2 subsets by activated
B cells has been shown to alter the isotype profile of Abs secreted by
such B cells. This is a result of differential effects of Th1- and
Th2-type cytokines on B cells. Thus, while IFN-
selectively induces
secretion of the IgG2aisotype of Abs, IL-4 promotes the production of
the IgG1 isotype (29, 30).
We have shown so far that the relative proportion of Th1 vis a vis Th2
cells recruited by G41CT3-primed B cells can be influenced by the
challenge Ag. It was logical, therefore, to expect that such Ag-driven
differences in Th subset recruitment by primed B cells should also, in
turn, reflect the level of differences in the proportion of IgG1 vs
IgG2a Abs secreted as the outcome of the B-T cognate interactions. To
verify this, we immunized BALB/c mice with a single dose of peptide
G41CT3, and the spleens were collected 3 wk later. Primed splenocytes
were then adoptively transferred into fresh, irradiated
recipients, which were then challenged with soluble forms of either
peptide G41CT3 or G28CT3. Relative levels of anamnestic IgG1 and IgG2a
titers were then measured from sera collected 6 days later; the results
are summarized in Figure 4
. While the
IgG1 levels were relatively uninfluenced by challenge Ag, serum IgG2a
levels were markedly enhanced in mice boosted with peptide G28CT3
relative to those boosted with peptide G41CT3 (Fig. 4
). These results
further confirm, at the functional level, our contention that
G41CT3-primed B cells recruit a larger proportion of Ag-specific Th1
cells when recalled with peptide G28CT3 as opposed to a restimulation
with peptide G41CT3. Further, this altered recruitment represents a
productive B-T interaction, with its expected consequences on the
secreted Ab isotype distribution.
|
Results described thus far indicate that G41CT3-primed B cells recruit a larger proportion of Ag-specific Th1 cells in the presence of peptide G28CT3 as opposed to peptide G41CT3. This, however, was not true in the case of either unprimed B cells or CT3-primed LNCs. Furthermore, we have also previously shown (10) that peptides G41CT3 and G28CT3 do not differ significantly in terms of processability upon uptake by APCs. Collectively, these data suggested that peptide-dependent differences in specific Ag uptake by the primed B cell population may account for the observed differences in interactions with the Th subsets. It was therefore of interest to examine the binding of both peptide G41CT3 and G28CT3 to the sIg receptors on G41CT3-primed B cells. However, purification in sufficient quantities and culture of Ag-specific B cells becomes difficult, particularly in a primary response, given their low frequencies of occurrence. This is especially true of peptide G41CT3, which has been shown to be poorly immunogenic (10). Consequently, we decided to employ mAbs generated against peptide G41CT3 as surrogates for the sIg receptor on G41CT3-primed B cells. Admittedly, however, the known low frequency of fusion renders it unlikely that a panel of mAbs generated will be representative of the actual repertoire of G41CT3-primed B cells generated in vivo. Nevertheless, results obtained with such mAbs should prove helpful in identifying a trend, if any exists.
mAbs of the IgG class were obtained from mice immunized with peptide G41CT3 after boosting with soluble Ag 28 days later. A total of five highly reactive (Materials and Methods) stabilized clones were obtained, all of which were found to be specific for the tetrapeptide sequence DPAF between positions four and seven, as identified by fine specificity mapping against overlapping hexapeptides, described earlier (data not shown; 10 . The low number of hybridomas obtained against peptide G41CT3 is probably a consequence of its poor immunogenicity (10).
All five of these mAbs were evaluated for their relative affinities for
the homologous peptide G41CT3 and the analogue, peptide G28CT3, by
competitive inhibition ELISA. In addition, we also measured the
on-rates of binding of either peptide to each of these mAbs in a
fluorescence quenching assay under pseudo first order conditions, as
described in Materials and Methods. The results from both
these sets of experiments are summarized in Table III
. All mAbs showed comparable
affinities for both peptide G41CT3 and G28CT3, except mAb G41.8 in
which the relative affinity for peptide G41CT3 was marginally higher
(Table III
). Interestingly, however, despite the largely comparable
affinities, dramatic differences in on-rates for binding to the two
peptides could be observed. In all cases, on-rates for mAb binding to
the heterologous peptide G28CT3 was markedly higher than that for the
homologous Ag G41CT3, with differences ranging from 3- to as much as
17-fold for mAb G41.8.
|
Peptides G41CT3 and G28CT3 do not differ in secondary structural characteristics
An attempt to rationalize the observed differences in the kinetics of recognition of the two peptides was made by examining the secondary structural properties by CD spectroscopy. Earlier, such studies had already revealed an equally random distribution of conformations in aqueous solution for both peptides (10). Nevertheless, we probed further for any subtle variations in either the secondary structure or propensities for it, for which purpose we employed the secondary structure-enhancing solvent, trifluoroethanol (TFE; 31 . Either the whole immunogen molecule (i.e., G41CT3 or G28CT3) or synthetic peptides representing only the B epitope segments (residues 115, G41 or G28) or the T cell epitope segment (residues 1838, peptide CT3) were carefully examined for their CD spectra in the presence of varying concentrations of TFE. However, such studies again proved unproductive in that no marked distinctions could be discerned. Thus, while both peptides G41CT3 and G28CT3 showed increased, but comparable, helical content with increasing TFE concentrations, this increase proved to result entirely from the CT3 segment (data not shown). The B epitope segments (G41 and G28), however, were equally resistant toward inducibility into any secondary structure, even at TFE concentrations as high as 50% (data not shown).
Peptides G41CT3 and G28CT3 show altered solution behavior
In contrast to the results described above, an analysis of the CD
spectra as a function of increasing peptide concentration proved
interesting. Such studies revealed a shift in the minima of the
negative peak to longer wavelengths (Fig. 5
, A and B). Such a
rightward shift at higher concentrations is usually indicative of the
presence of intermolecular associations. This association, however, did
not represent peptide aggregationat least in the sense that it is
generally understoodin that a simple dilution was sufficient to
regenerate the profile obtained at lower concentrations for both
peptides. Thus, dilution from a 60-µM peptide solution to
concentrations of either 20 or 6 µM readily reproduced the spectra
depicted in Figure 5
, A and B, for the
corresponding concentrations. The intermolecular associations observed
at higher concentrations, therefore, apparently represent weak
interactions.
|
|
The kinetics of Ag recognition is also dependent upon peptide concentration
The biophysical studies described in Figures 5
and 6
were
performed in an attempt to rationalize the differences in recognition
of the two peptides G41CT3 and G28CT3 by anti-G41CT3 mAbs. The only
distinction, with respect to behavior in solution, that became apparent
from these studies was in the nature of the intermolecular interactions
that these two peptides are involved in at higher concentrations. It
was of interest, therefore, to determine whether these differences
could account for the observed alteration in binding behavior. For this
purpose, we selected mAb G41.14 as a representative anti-G41CT3
mAb. A 100-nM concentration of mAb G41.14 was incubated in the presence
of 2, 6, or 20 µM final concentrations of either peptide G41CT3 or
peptide G28CT3, and the rate of binding was measured as quenching of
tryptophan fluorescence over a period of 60 min. The resulting slopes
obtained were then plotted against peptide concentrations; the linear
regression fits are shown in Figure 7
. An
interesting divergence became evident from these results. While binding
rates were only marginally affected with increasing G41CT3
concentrations, indicative of a true pseudo first order reaction,
peptide G28CT3 binding rates were dramatically influenced (Fig. 7
).
Surprisingly, at 2-µM concentrations, binding rates were comparable
for both peptides. However, peptide G28CT3 became markedly more
efficient relative to peptide G41CT3 at the 6-µM concentration, which
was further enhanced when the peptide concentration was increased to 20
µM (Fig. 7
).
|
The ability of peptide G28CT3 to induce B cell-mediated Th1 stimulation correlates with its concentration-dependent differences in kinetic behavior
Our above-mentioned finding (Fig. 7
) that the on-rate of peptide
G28CT3 binding to an anti-G41CT3 mAb was dependent on peptide
concentration also prompted us to assess the effect of peptide dose on
relative activation of Th subsets. For this assessment, G41CT3-primed B
cells along with CT3-primed T cells were cultured in the presence of
varying amounts of either peptide G41CT3 or G28CT3, and levels of IL-10
and IFN-
, as prototypic Th2 and Th1 cytokines, respectively, were
measured in the culture supernatants. The results of such an
experiment are shown in Figure 8
A. When peptide G41CT3 was
employed as recall Ag, the relative dominance of IL-10 over IFN-
remained invariant over all the concentrations tested (Fig. 8
A). This was, however, not the case for peptide G28CT3 in
which a pronounced IL-10 dominance at low concentrations inverted to
IFN-
dominance as the peptide concentration was increased (Fig. 8
A). These results clearly show that whereas peptide G28CT3
induced a dose-dependent switch in the dominance of Th2 to the Th1 type
of cytokines, peptide G41CT3 was unable to do so over the concentration
range evaluated. Unfortunately, higher concentrations could not be
tested because both peptides proved toxic at doses beyond those
described (data not shown).
|
at doses relevant to those employed in Figure 7
ratios
elicited by peptide G41CT3 remain relatively unaffected over the
concentration range depicted (Fig. 8| Discussion |
|---|
|
|
|---|
Interesting, new insights have recently been provided that further our understanding of APC-driven differential activation of CD4 effector subsets. For instance, Murray et al. (22) have demonstrated that ligand density available on an APC surface for T cell recognition plays an important role in promoting relative differentiation of Th subsets. A high ligand density was found to favor Th1 differentiation, whereas a low ligand density is biased toward Th2 differentiation (22). Notably, a display of high ligand density by B cells has also been shown to preferentially stimulate Th1-like immunity (32). Recent results also suggest that the selective generation of Th1 vs Th2 effectors may be regulated by the strength of signal delivered by TCR upon engagement by the MHC class II-peptide complex on APCs (33). It is therefore now becoming apparent that differentiation/stimulation of CD4 effector subsets is not rigidly APC restricted, but is also subject to influence by extraneous parameters. The basis for ligand density-dependent modulation of CD4 effector pathways has been suggested to reside in differences in thresholds of activation required for Th1 vs Th2 cells (34).
Our present studies provide further evidence to support a role for ligands in determining APC-mediated selectivity in Th subset activation. Here, we employed a pair of analogous peptides, which although differing in sequence at two positions were nevertheless previously shown to be invariant with respect to both the fine specificity of B cells induced and their ability to prime T cells for a proliferative response (10). Notably, however, peptide G28CT3 proved superior to peptide G41CT3 at inducing a T cell recall response by G41CT3-primed B cells (10). In this report, we have extended these observations by demonstrating that, in addition to quantitative differences, peptides G41CT3 and G28CT3 also induce qualitatively distinct T cell recall responses from a common pool of Ag-specific T cells. Thus, for example, while an in vitro challenge of G41CT3-primed LNCs with the homologous peptide G41CT3 yielded predominantly Th2-type cytokines, a marked enhancement of Th1 activation was observed from the same culture when the recall Ag employed was the heterologous peptide, G28CT3. Subsequent experiments verified that these differences in recall abilities was a consequence of G41CT3-primed B cells serving as APCs. Particularly relevant here was our demonstration that enriched G41CT3-primed B cells recruited a significantly higher proportion of Th1 cells from a CT3-primed T cell pool in the presence of peptide G28CT3 rather than peptide G41CT3. Further, our observations that neither unprimed B cells nor CT3-primed LNCs were susceptible to peptide-mediated influences collectively imply an interaction between primed B cell and the B cell epitope on Ag as the putative causatory factor for the altered Th recruitment profiles. Finally, the physiologic validity of our in vitro findings was amply demonstrated in adoptive transfer experiments showing that anamnestic responses of G41CT3-primed B cells contained an enhanced proportion of the IgG2a isotype of Abs, relative to IgG1, on boosting with peptide G28CT3 as opposed to boosting with peptide G41CT3.
The Ag-presenting efficacy of primed B cells is dictated both by the efficiency of Ag capture through sIg receptors and the efficiency of processing. We have shown earlier that peptides G28CT3 and G41CT3 do not differ significantly in terms of processability subsequent to uptake by APCs (10). This, therefore, left the possibility that the observed differences in Ag-mediated recruitment of Th subsets could result from differential recognition of the two peptide Ags by sIg receptors on G41CT3-primed B cells. Because of the difficulties associated with obtaining large amounts of G41CT3-primed B cells, we employed anti-G41CT3 mAbs as surrogates for sIgG receptors to probe for differences in binding properties of peptides G41CT3 and G28CT3. Interestingly, while all mAbs tested displayed comparable affinities for both peptides, the kinetics of this binding proved to be markedly different. Significantly higher on-rates of binding were obtained for peptide G28CT3 relative to peptide G41CT3, although the magnitude of this difference varied from 3- to 17-fold depending on the mAb. We believe that the uniformity of these results permits an extrapolation to suggest that similar differences could also apply to the sIgG receptors on G41CT3-primed B cells.
Although no significant inherent differences in secondary structural propensities could be detected between the two peptides, we were able to identify concentration-dependent alterations in solution behavior. CD studies in a high ionic strength solution revealed that the intermolecular associations engaged in by molecules of the two peptides G41CT3 and G28CT3 at higher concentrations were of a qualitatively distinct nature. The salt disruptability of associations seen for peptide G41CT3 was indicative of interactions that are predominantly hydrophilic (or ionic?). In contrast, the stabilizing effect of salt on the CD spectrum of peptide G28CT3 revealed the occurrence of intermolecular associations that are composed almost exclusively of hydrophobic interactions.
The sole distinction in biophysical properties, detectable as qualitative differences in the nature of their intermolecular associations, prompted us to suspect that these differences could also account for differences in the binding behavior of the two peptides. Such a presumption was subsequently confirmed by the results of an experiment wherein we measured binding rates of both peptides to an anti-G41CT3 mAb as a function of varying peptide concentration. The rate of peptide G28CT3 binding to the mAb was found to be profoundly influenced by peptide concentration, with a marked increase at higher concentrations. In contrast, the binding rate for peptide G41CT3 was relatively insensitive to concentration effects with, in fact, a marginal decrease at higher concentrations. The concentration dependence of differences in on-rates of mAb binding to the two peptides clearly implicates the operation of concentration-dependent differences in B cell epitope presentation, which, in turn, may be explained by invoking our results on the variant nature of the intermolecular association of peptides G41CT3 and G28CT3. It is possible that the differences in such weak interactions may be sufficient to alter the kinetics of Ag-Ab interactions, although too weak to influence equilibrium binding parameters such as affinity.
Having demonstrated a direct correlation between the kinetics of Ag
binding and the concentration-dependent behavior of peptide G28CT3 in
solution, it remained for us to ascertain whether these factors could,
in fact, be responsible for the altered B cell-mediated Th subset
recruitment profiles by peptide G28CT3 compared with peptide G41CT3. To
verify this, we examined the effect of varying peptide
concentrations on the ability of G41CT3-primed B cells to elicit Th1-
vs Th2-type cytokines from a population of CT3-primed T cells. The
results of these experiments proved extremely interesting. While
relative predominance of the Th2 cytokines was independent of the dose
of peptide G41CT3, a clear transition from a Th2 to Th1 dominance was
observed when peptide G28CT3 concentrations were increased. A
comparison of the peptide concentrations required for the switch and
also of IL-10/IFN-
ratios, with changes in kinetic and biophysical
behavior, all as a function of increasing peptide concentration,
revealed striking similarities. This strongly suggests an
etiologic relationship between alterations in solution properties of
peptide G28CT3, the kinetics of its binding, and its ability to elicit
altered cytokine profiles from a primed T cell population in the
presence of G41CT3-activated B cells.
The mechanism by which the altered nature of intermolecular associations in peptide G28CT3 promotes binding remains an issue of particular interest. One possibility is that such interactions render the B cell epitope more accessible to recognition, thereby increasing the probability of productive collisions leading to a binding interaction. Alternatively, intermolecular interactions may also facilitate Th1 recruitment by ensuring simultaneous, multiple occupancy of recognition sites within either sIg receptors or Ab molecules, leading in the former case to an increased strength of the intracellular signal generated. A more definitive conclusion must, however, await detailed analysis.
Our demonstration here of Ag-induced variability in B cell-mediated Th subset activation profiles adds yet another level of intricacy to our current understanding of the processes that mediate between immune recognition and the qualitative nature of an immune response. It will be particularly interesting to evaluate the significance of these findings in polarizing effector responses in infectious disease situations (35). It would also be interesting to elucidate the mechanism by which the alterations in Ag binding kinetics by B cells modulate their Ag-presenting properties. At present, several alternate possibilities may be invoked. For example, at an empirical level, an increased rate of binding may simply correspond to increased Ag uptake, rapidly leading to a high density of ligand presentation. As discussed earlier, high ligand densities have been proposed to favor Th1 activation (22, 34). A related factor that also needs consideration stems from the recent demonstration that the nature of Ag-BCR interaction directly influences intracellular targeting of Ag to lysozomes, for eventual processing and presentation (36). While this has been shown to quantitatively influence T cell activation (36), qualitative distinctions, if any, remain to be examined. Finally, the possibility that Ag binding kinetics may differentially regulate the extent of B cell activationwith its consequent effects on up-regulation of one or more cell surface accessory molecules involved in cognate B-T interaction (37, 38, 39, 40, 41)also cannot be excluded. Discriminating between these and perhaps other alternatives is a current emphasis in our laboratory.
In summary, we have demonstrated here that relative recruitment of Th1 vs Th2 subsets of Ag-activated T cells by Ag-primed B cells is not invariant but, rather, is modulated by the kinetics of Ag recognition through its sIg receptor. While the default pathway is biased toward Th2 recruitment, higher on-rates of binding promote increased Th1 activation. Also of note is our finding that even subtle alterations in solution structure, resulting from minor changes in amino acid sequence, can so markedly influence the outcome of a cognate interaction between Ag-activated B and T cells. These findings may also bear implications for molecular mimicry, wherein homologous B cell epitopes could differentially skew Th effector responses with the potential for pathogenic consequences if one of the epitopes happens to derive from a self Ag.
| Acknowledgments |
|---|
| Footnotes |
|---|
2 Abbreviations used in this paper: sIg, surface Ig; LNCs, lymph node cells; CD, circular dichroism; BCR, B cell Ag receptor; TFE, trifluoroethanol. ![]()
Received for publication March 4, 1998. Accepted for publication June 29, 1998.
| References |
|---|
|
|
|---|
stimulates IgG2a secretion by murine B cells stimulated with bacterial lipopolysaccharide. J. Immunol. 140:2121.[Abstract]
This article has been cited by other articles:
![]() |
L. Vijayakrishnan, K. Natarajan, V. Manivel, S. Raisuddin, and K. V. S. Rao B Cell Responses to a Peptide Epitope. IX. The Kinetics of Antigen Binding Differentially Regulates Costimulatory Capacity of Activated B Cells J. Immunol., June 1, 2000; 164(11): 5605 - 5614. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Nakra, V. Manivel, R. A. Vishwakarma, and K. V. S. Rao B Cell Responses to a Peptide Epitope. X. Epitope Selection in a Primary Response Is Thermodynamically Regulated J. Immunol., June 1, 2000; 164(11): 5615 - 5625. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Saboori, N. R. Rose, S. C. Yuhasz, L. M. Amzel, and C. L. Burek Peptides of Human Thyroglobulin Reactive with Sera of Patients with Autoimmune Thyroid Disease J. Immunol., December 1, 1999; 163(11): 6244 - 6250. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |